Keryx Biopharmaceuticals Inc. (KERX)
Symbol Info
Listed Symbol KERX
Name Keryx Biopharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2017-12-31
Latest Fiscal Revenue $60,641,000
Latest Fiscal EPS $-1.43
Price Info
21 Day Moving Average $3.0833
21 Day EMA $3.179040
50 Day Moving Average $3.0562
50 Day EMA $3.137780
200 Day EMA $3.835500
200 Day Moving Average 3.946300
52 Week High $5.98
52 Week Low $2.47
52 Week Change $-24.663700
Alpha -0.016125
Beta 1.7866
Standard Deviation 0.173237
R2 0.105236
Periods 60
Share Information
10 Day Average Volume 819,930
20 Day Average Volume 1,432,430
30 Day Average Volume 1,380,312
50 Day Average Volume 1,162,079
Outstanding Shares 120,375,926
Float Shares 112,754,495
Percent Float 93.67%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 263
Institute Holdings Date 2018-11-30
Institute Bought Previous 3 Months 3,885,182
Institute Holdings Percent 73.100000
Institute Sold Previous 3 Months 3,000,716
Insider Holdings Date 2018-11-30
Insider Bought Previous 3 Months -
Insider Holdings Percent 6.30%
Insider Sold Previous 3 Months 6,858
Insiders Shares Owned 7,621,431
Price Change
7 Day Price Change $-
7 Day Percent Change -
21 Day Price Change $0.3599999
21 Day Percent Change 12.00%
30 Day Price Change $0.6599999
30 Day Percent Change 24.44%
Month To Date Price Change $0.3500
Month To Date Percent 11.63%
90 Day Price Change $0.400000
90 Day Percent Change 13.51%
Quarter To Date $-0.04
Quarter To Date Percent -1.18%
180 Day Price Change $-1.83
180 Day Percent Change -35.26%
200 Day Price Change $-1.92
200 Day Percent Change -36.36%
Year To Date $-1.29
Year To Date Percent -27.74%
Profile
Description Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
Details
Issue Type CS
Market Cap $404,463,111
Sec Type EQS
Auditor UHY LLP
Total Shares Outstanding -
CEO
Employees 189
Last Audit UQ
Classification
CIK 0001114220
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address One Marina Park Drive, 12th Floor
Boston, MA 2210
Website http://www.keryx.com
Facisimile +1 617 466-3501
Telephone +1 617 466-3500
Email IR@keryx.com
Key Ratios
Profitability
EBIT Margin -30.4
EBITDA Margin -29.4
Pre-Tax Profit Margin -672.8
Profit Margin Cont -96.41
Gross Margin 62.50
Profit Margin TOT -96.41
Income Statements
Revenue $94,218,000
Revenue Per Share $0.7827
Revenue 3 Years $90.54
Revenue 5 Years $67.14
Valuation Measures
PE Ratio -
Enterprise Value $510,619,111
Price To Sales 4.292843
Price To Free Cash -4.1
PE High Last 5 Years -
Price To Book 61.6
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -7
Financial Strength
Total Debt To Equity -
Int Coverage -0.5
Current Ratio 2.2
Leverage Ratio -4.2
Quick Ratio 1.0
Long Term Debt To Capital -
Assets
Receivables Turnover 4.3
Invoice Turnover 0.80
Assets Turnover 0.20
Management Effectiveness
Return Assets -55.8
Return On Equity 401.43
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
KERX
Keryx Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.